A Look into High Resolution Melting Industry……Deep Analysis…..
Global High
Resolution Melting (HRM) market is expected to reach USD 131.7 billion by 2022 according to a new report by Grand View
Research Inc. Increasing incidences of
cancer, sickle cell anemia, HIV and other STDs are expected to positively
reinforce demand for smart and simple molecular diagnostics. According to the
Genetic and Rare Diseases Center (GARD) in 2014, 10% of the U.S. population
that is nearly 30 million people were suffering from genetic disorders. Some
key disease statistics are reported below:
Biopharmaceutical innovators are at the
forefront of the human response to the coronavirus pandemic. A significant
number of major biotech firms are in the midst of a race to investigate the
Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the
speed of response to SARS/MERs etc, the biotech entities are investigating
SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are
being put into the R&D. With multiple candidates in trial, the public and
private sectors are anticipated to work in unison for the foreseeable period,
until a vaccine is developed for Covid-19. The report will account for Covid19
as a key market contributor.
As per the estimates provided by CDC,
number of acute cases of hepatitis C reported in the United States increased
from 1,778 to 2,138 from 2012 to2013. According to the UNAIDS report, out of
the 36.9 million people that are suffering with HIV/AIDS, 17.1 million are
unaware about disease occurrence due to unavailability of testing services
As per the WHO estimates in 2015,
there are over 130-150 million people suffering with HCV globally
Based on analyzing the disease trends
and relatively lower treatment rates suggests that the demand for gene mutation
and other genomic tests are expected to increase significantly over the next
few years. Recent developments in the field of QPCR, next generation
sequencing, genomics and big data analytics have been instrumental in
strengthening the precision medicine approach. The U.S. FDA has already
approved some of the treatments which are designed to meet the requirements of
a specific genetic makeup or the genomic profile of the patient’s tumor.
To Request Sample Copy of this report, click the link:
For instance, the U.S FDA has approved
a new treatment for cystic fibrosis (CF) in January, 2012. The drug kalydeco
was approved for patients reported to have a specific genetic mutation known as
“G551D mutation. The number of mutations which can lead to CF is in hundreds,
and the G551D mutation is responsible for nearly 4% of the cases in the U.S.
Furthermore, in 2015, the Obama
administration has announced the Precision Medicine Initiative with an
investment of USD 216 million in the 2016 president's budget. This initiative
is expected to positively reinforce the HRM analysis market over the forecast
period.
Further key findings from the study suggest:
·
In 2014, North America
dominated the overall HRM analysis market with a share of nearly 42%. Key
factors attributed are high disease prevalence rates, presence of large number
of academic universities; strong pharmaceutical and biotech industry, presence
of large number genetic testing centers, and rapid adoption of novel
technologies for improving the healthcare outcomes.
·
Asia pacific is identified as
the fastest growing region over the forecast period. Key reasons attributed are
increasing public and private expenditure on molecular diagnostics and genetic
testing, increasing prevalence of genetic disorders, and increasing burden of
chronic diseases such as cancer, COPD, HIV and others.
·
Key market players in the High
Resolution Melting analysis market include, Roche Molecular Systems, Idaho
Technology Corporation, Kapa Biosystems, Thermo Fisher Scientific, Premier
Biosoft and Qiagen. Furthermore, Roche Molecular Systems leads the industry
with the highest R&D expenditure and commands a significant market
share.
The
global high resolution melting analysis market size was valued at USD 75.3
million in 2016 and is expected to grow at a CAGR of 9.8% during the forecast
period. Increasing investment in R&D, growing applications of this
technology in epigenetics, and mutation scanning are some of the factors
propelling the market growth. Benefits such as no use of probes, closed tube
system, prevention of post-PCR sample contamination, and high accuracy of
melting profile analysis are driving the HRM analysis market growth.
The market dynamics indicate that
various players operating in this space compete, based on product
specifications, such as reagents, software & instrument capabilities, and
prices. The technology used to manufacture, quality of the product, and sample
processing capacity are the key variables expected to impact the usage rates of
these products. Increasing collaboration between government bodies and major
players to introduce technologically advanced products and reduce overall healthcare
costs is expected to further intensify the HRM analysis market competition.
Factors such as growing prevalence of
chronic diseases, rising demand for personalized medicine and favorable
government initiatives are expected to have a positive impact on the HRM
analysis market. Personalized medicine, which is also known as precision
medicine, is an innovative and powerful approach to prevent and treat the
disease after considering the differences in different genetic combinations,
lifestyle, and environmental factors.
Browse Press
Release of this report:
Grand View Research has segmented the High
Resolution Melting analysis market on the basis of product, end-use,
application:
High Resolution Melting Analysis Market Product Outlook,
by Revenue (USD Million, 2015 - 2022)
·
Instruments
·
Reagents
·
Software
High Resolution Melting Analysis Market End-Use Outlook,
by Revenue (USD Million, 2015 - 2022)
·
Academic Researcher
·
Clinical Diagnostics
High Resolution Melting Analysis Market Application
Outlook by Revenue (USD Million, 2015 - 2022)
·
Detection of Acquired
Mutations/Mutation Scanning/SNP Typing
·
Microbial Species
Identification
·
Zygosity testing
·
Epigenetics/ Methylation Profiling
and drug-resistant
About Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
Comments
Post a Comment